You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
San Carlos, California
52 Week High
52 Week Low
Seeking AlphaMay 18
Iovance Biotherapeutics: Updating The Investment Thesis
We revisit this promising developmental firm and its evolving investment case in the paragraphs below. We highlight recent trial data and what analysts are saying on the company. "Long books, when read, are usually overpraised, because the reader wishes to convince others and himself that he has not wasted his time.” ― E.M. Forster, Aspects of the Novel Iovance Biotherapeutics (IOVA) is one of several small biotech holdings making big moves this week for the Busted IPO Forum model portfolio. The company ...
Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward
Shares of small-cap biotech Iovance Biotherapeutics Inc (NASDAQ: IOVA) were making a strong upward move Thursday on more than 10 times their average volume.
The Motley FoolMay 8
Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2019 Earnings Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Iovance Biotherapeutics first-quarter 2019 financial results conference call. [Operator instructions] Please be advised that the call is being recorded at the company's request. Now I would like to turn the conference over to Tim Morris, chief financial officer at Iovance. Sir, please go ahea...
-$0.29 per share
-$0.30 per share